Publikation:

Recent advances in cancer immunotherapy

Lade...
Vorschaubild

Dateien

Sun_2-15vis3cdtrm3r2.pdf
Sun_2-15vis3cdtrm3r2.pdfGröße: 862.2 KBDownloads: 139

Datum

2021

Autor:innen

Sun, Qiang
Melino, Gerry
Jiang, Jingting
Wang, Ying
Shi, Yufang

Herausgeber:innen

Kontakt

ISSN der Zeitschrift

Electronic ISSN

ISBN

Bibliografische Daten

Verlag

Schriftenreihe

Auflagebezeichnung

ArXiv-ID

Internationale Patentnummer

Link zur Lizenz

Angaben zur Forschungsförderung

Projekt

Open Access-Veröffentlichung
Open Access Hybrid
Core Facility der Universität Konstanz

Gesperrt bis

Titel in einer weiteren Sprache

Publikationstyp
Zeitschriftenartikel
Publikationsstatus
Published

Erschienen in

Discover Oncology. Springer New York. 2021, 12(1), 27. ISSN 1868-8497. eISSN 1868-8500. Available under: doi: 10.1007/s12672-021-00422-9

Zusammenfassung

Cancer immunotherapy represents a major advance in the cure of cancer following the dramatic advancements in the development and refinement of chemotherapies and radiotherapies. In the recent decades, together with the development of early diagnostic techniques, immunotherapy has significantly contributed to improving the survival of cancer patients. The immune-checkpoint blockade agents have been proven effective in a significant fraction of standard therapy refractory patients. Importantly, recent advances are providing alternative immunotherapeutic tools that could help overcome their limitations. In this mini review, we provide an overview on the main steps of the discovery of classic immune-checkpoint blockade agents and summarise the most recent development of novel immunotherapeutic strategies, such as tumour antigens, bispecific antibodies and TCR-engineered T cells.

Zusammenfassung in einer weiteren Sprache

Fachgebiet (DDC)
570 Biowissenschaften, Biologie

Schlagwörter

Cancer immunotherapy, Immune check point blockade, T cell receptor, Cancer survival, p53, KRas

Konferenz

Rezension
undefined / . - undefined, undefined

Forschungsvorhaben

Organisationseinheiten

Zeitschriftenheft

Zugehörige Datensätze in KOPS

Zitieren

ISO 690SUN, Qiang, Gerry MELINO, Ivano AMELIO, Jingting JIANG, Ying WANG, Yufang SHI, 2021. Recent advances in cancer immunotherapy. In: Discover Oncology. Springer New York. 2021, 12(1), 27. ISSN 1868-8497. eISSN 1868-8500. Available under: doi: 10.1007/s12672-021-00422-9
BibTex
@article{Sun2021-12Recen-56461,
  year={2021},
  doi={10.1007/s12672-021-00422-9},
  title={Recent advances in cancer immunotherapy},
  number={1},
  volume={12},
  issn={1868-8497},
  journal={Discover Oncology},
  author={Sun, Qiang and Melino, Gerry and Amelio, Ivano and Jiang, Jingting and Wang, Ying and Shi, Yufang},
  note={Article Number: 27}
}
RDF
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/56461">
    <dc:contributor>Shi, Yufang</dc:contributor>
    <dcterms:abstract xml:lang="eng">Cancer immunotherapy represents a major advance in the cure of cancer following the dramatic advancements in the development and refinement of chemotherapies and radiotherapies. In the recent decades, together with the development of early diagnostic techniques, immunotherapy has significantly contributed to improving the survival of cancer patients. The immune-checkpoint blockade agents have been proven effective in a significant fraction of standard therapy refractory patients. Importantly, recent advances are providing alternative immunotherapeutic tools that could help overcome their limitations. In this mini review, we provide an overview on the main steps of the discovery of classic immune-checkpoint blockade agents and summarise the most recent development of novel immunotherapeutic strategies, such as tumour antigens, bispecific antibodies and TCR-engineered T cells.</dcterms:abstract>
    <dc:rights>Attribution 4.0 International</dc:rights>
    <dcterms:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/"/>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/56461"/>
    <dc:creator>Wang, Ying</dc:creator>
    <dcterms:issued>2021-12</dcterms:issued>
    <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/56461/1/Sun_2-15vis3cdtrm3r2.pdf"/>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:creator>Sun, Qiang</dc:creator>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dc:creator>Melino, Gerry</dc:creator>
    <dc:creator>Amelio, Ivano</dc:creator>
    <dc:language>eng</dc:language>
    <dc:creator>Jiang, Jingting</dc:creator>
    <dc:contributor>Jiang, Jingting</dc:contributor>
    <dcterms:title>Recent advances in cancer immunotherapy</dcterms:title>
    <dc:contributor>Melino, Gerry</dc:contributor>
    <dc:contributor>Wang, Ying</dc:contributor>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2022-02-09T10:31:59Z</dc:date>
    <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/56461/1/Sun_2-15vis3cdtrm3r2.pdf"/>
    <dc:contributor>Amelio, Ivano</dc:contributor>
    <dc:contributor>Sun, Qiang</dc:contributor>
    <dc:creator>Shi, Yufang</dc:creator>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2022-02-09T10:31:59Z</dcterms:available>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
  </rdf:Description>
</rdf:RDF>

Interner Vermerk

xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter

Kontakt
URL der Originalveröffentl.

Prüfdatum der URL

Prüfungsdatum der Dissertation

Finanzierungsart

Kommentar zur Publikation

Allianzlizenz
Corresponding Authors der Uni Konstanz vorhanden
Internationale Co-Autor:innen
Universitätsbibliographie
Nein
Begutachtet
Unbekannt
Diese Publikation teilen